Rocket Pharmaceuticals Inc (RCKT)
22.79
+0.27
(+1.20%)
USD |
NASDAQ |
May 02, 16:00
22.79
0.00 (0.00%)
After-Hours: 20:00
Rocket Pharmaceuticals Enterprise Value: 1.665B for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 1.665B |
| April 30, 2024 | 1.574B |
| April 29, 2024 | 1.604B |
| April 26, 2024 | 1.616B |
| April 25, 2024 | 1.627B |
| April 24, 2024 | 1.765B |
| April 23, 2024 | 1.769B |
| April 22, 2024 | 1.787B |
| April 19, 2024 | 1.690B |
| April 18, 2024 | 1.752B |
| April 17, 2024 | 1.770B |
| April 16, 2024 | 1.822B |
| April 15, 2024 | 1.800B |
| April 12, 2024 | 1.816B |
| April 11, 2024 | 1.915B |
| April 10, 2024 | 1.837B |
| April 09, 2024 | 1.921B |
| April 08, 2024 | 1.834B |
| April 05, 2024 | 1.890B |
| April 04, 2024 | 1.888B |
| April 03, 2024 | 1.928B |
| April 02, 2024 | 1.953B |
| April 01, 2024 | 2.045B |
| March 28, 2024 | 2.065B |
| March 27, 2024 | 2.093B |
| Date | Value |
|---|---|
| March 26, 2024 | 2.031B |
| March 25, 2024 | 2.061B |
| March 22, 2024 | 2.089B |
| March 21, 2024 | 2.135B |
| March 20, 2024 | 2.148B |
| March 19, 2024 | 2.059B |
| March 18, 2024 | 2.027B |
| March 15, 2024 | 2.053B |
| March 14, 2024 | 2.096B |
| March 13, 2024 | 2.175B |
| March 12, 2024 | 2.076B |
| March 11, 2024 | 2.125B |
| March 08, 2024 | 2.149B |
| March 07, 2024 | 2.118B |
| March 06, 2024 | 2.140B |
| March 05, 2024 | 2.120B |
| March 04, 2024 | 2.225B |
| March 01, 2024 | 2.390B |
| February 29, 2024 | 2.279B |
| February 28, 2024 | 2.254B |
| February 27, 2024 | 2.409B |
| February 26, 2024 | 2.323B |
| February 23, 2024 | 2.277B |
| February 22, 2024 | 2.251B |
| February 21, 2024 | 2.203B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
177.48M
Minimum
May 11 2022
3.577B
Maximum
Feb 08 2021
1.280B
Average
1.121B
Median
Enterprise Value Benchmarks
| ADMA Biologics Inc | 1.601B |
| Geron Corp | 1.973B |
| Madrigal Pharmaceuticals Inc | 3.661B |
| Ligand Pharmaceuticals Inc | 1.095B |
| Puma Biotechnology Inc | 241.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -59.66M |
| Total Expenses (Quarterly) | 63.28M |
| EPS Diluted (Quarterly) | -0.64 |
| Earnings Yield | -12.90% |